Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer The overall survival rate at 5 years was ...
Iodine-123 Metaiodobenzylguanidine Scintigraphy Scoring Allows Prediction of Outcome in Patients With Stage 4 Neuroblastoma: Results of the Cologne Interscore Comparison Study Medline, Embase, CINAHL, ...
Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more than two decades without clinical progress, the addition of programmed cell death protein 1 axis blockade to ...
Integrating Evidence-Based Medicine for Treatment of Spinal Metastases Into a Decision Framework: Neurologic, Oncologic, Mechanicals Stability, and Systemic Disease Primary CNS lymphoma (PCNSL) is a ...
In a phase II trial, 99 patients were randomly assigned to bevacizumab 7.5 (n = 32) or 15 mg/kg (n = 35) plus carboplatin (area under the curve = 6) and paclitaxel (200 mg/m 2) every 3 weeks or ...
Why Are We Failing to Do What Works? Musings on Outpatient Palliative Care Integration in Cancer Care Neuroendocrine tumors (NETs) are a heterogeneous clinical entity with a broad range of grade, pace ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
View all available purchase options and get full access to this article. Supported by the National Institutes of Health T32 CA009599 and The University of Texas MD Anderson Cancer Center support grant ...
We identified 14 trials (N = 12,567) submitted to US Food and Drug Administration since 2003 of treatments for advanced NSCLC. Only randomized, active-controlled trials with more than 150 patients ...
View all available purchase options and get full access to this article. Supported in part by the National Institute of Health (NIH), National Institute on Aging (NIA), Beeson Career Development Award ...
In a longitudinal clinical study to compare two groups, the primary end point is often the time to a specific event (eg, disease progression, death). The hazard ratio estimate is routinely used to ...
Prolonged and disabling fatigue is prevalent after cancer treatment, but the early natural history of cancer-related fatigue (CRF) has not been systematically examined to document consistent presence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results